UptalDPatelMD

Nephrology • Durham, NC

Acute Renal Failure, Hypertension, Kidney & Pancreas Transplantation

Associate Professor, Medicine, Duke University School of Medicine

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patel's full profile

Already have an account?

Office
4101 N Roxboro St
Durham, NC 27704
Phone+1 919-684-8111

Education & Training

University of MichiganFellowship, Nephrology, 2003 - 2005
University of MichiganFellowship, Pediatric Nephrology, 2001 - 2003
University of MichiganResidency, Internal Medicine/Pediatrics, 1997 - 2001
University of California San Francisco School of MedicineClass of 1997

Certifications & Licensure

NC State Medical License 2005 - 2018

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant Start of enrollment: 2012 Jun 01
Completed
Phase 1
Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD) Start of enrollment: 2014 May 01
Completed
Not Applicable

Publications & Presentations

PubMed

Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.
Hiddo J L Heerspink, Vlado Perkovic, Katherine R Tuttle, Pablo E Pergola, Kenneth W Mahaffey
Journal of the American Society of Nephrology. 2024-12-01
Clinical Outcomes Among High-Risk Primary Care Patients With Diabetic Kidney Disease: Methodological Challenges and Results From the STOP-DKD Study.
Hayden B Bosworth, Uptal D Patel, Allison A Lewinski, Clemontina A Davenport, Jane Pendergast
Medical Care. 2024-10-01
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.
Brad H Rovin, Pierre M Ronco, Jack F M Wetzels, Sharon G Adler, Isabelle Ayoub
Kidney International Reports. 2024-09-01

Lectures

Clinical Research in Nephrology: Trials, Trends, and Tools
American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/9/2019

Press Mentions

Kidney Disease Rates Have Stabilized in U.SNovember 7th, 2015
New Strategies for Combatting Chronic Kidney Disease, Other Long-Term ConditionsJune 25th, 2015
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)November 3rd, 2023
Join now to see all

Grant Support

Barriers To Optimal Cardiovascular Medication Use In Diabetes And Renal DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2010